Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912706141> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2912706141 endingPage "3137" @default.
- W2912706141 startingPage "3137" @default.
- W2912706141 abstract "Abstract Introduction Patients (pts) with CLL who achieve blood or bone marrow (BM) undetectable minimal residual disease (U-MRD), assessed with a sensitivity of at least 10-4 (MRD4), have long PFS after 1st-line treatment with FCR. A proportion of pts with mutated immunoglobulin heavy chain variable gene (M-IGHV) may be cured of CLL, given the reported PFS beyond 10 yrs. In contrast, most pts with unmutated (UM)-IGHV relapse, despite achieving BM U-MRD4. The likelihood of relapse and relapse kinetics relate to CLL biology, including depth of remission and proliferation rate. MRD testing using next generation sequencing (NGS) can achieve sensitivity up to 10-6 (MRD6) and can also be used to test for circulating tumor DNA in plasma, which may reflect residual tumor in the tissue (eg. lymph nodes), not detectable in the cellular fraction of blood or BM. To better assess the depth of remission following first-line FCR treatment for CLL, we performed NGS MRD6 testing in BM, peripheral blood mononuclear cells (PBMC) and plasma of pts enrolled in a single center, prospective, phase II study. All pts had BM U-MRD4 by 4-color flow cytometry (FLC) at the end of treatment (EOT). Methods The following EOT samples from 62 pts were analyzed for MRD6: 57 BM, 29 PBMC and 32 plasma. Adaptive Biotechnologies' NGS MRD assay uses multiplex PCR and NGS to amplify rearrangements within the B cell receptor CDR3 and identify disease associated clonotypes. Specifically, the assay utilizes multiplexed primers complementing V-J rearrangements (IGH, IGK/L) and D-J (IGH) rearrangements. Pre-treatment samples were sequenced to determine the malignant clonotype, which was then quantitated in the EOT samples, within the polyclonal background. Results Regardless of assay sensitivity, U-MRD rates by HTS according to sample type were: 14/57 (25%) in BM; 16/29 (55%) in PBMC; 24/32 (75.0%) in plasma. All pts with MRD+ in plasma simultaneously had detectable disease in either BM or PBMC. Of 16 pts who had U-MRD in PBMC, 7/12 with simultaneous BM samples were MRD+ in BM. In all patients, there was a trend toward increased likelihood of U-MRD in pts with M-IGHV [12/30 (40%) vs 4/24 (17%), OR 3.3 (0.9-12.2), p = 0.06]. Assay sensitivity varies according to amount of DNA in the sample and with malignant clonotype. Sensitivity of at least 10-6 was achieved in 74% and 62% of samples in BM and PBMC, respectively. Among patients with U-MRD by NGS: 4/14 BM (1.06-3.2 x 10-6, median 1.96 x 10-6) and 8/16 PBMC (1.001 x 10-6 to 3.56 x 10-6, median 1.54 x 10-6) samples did not have sensitivity of 10-6. Notably, 3 pts also had detectable disease at a level <10-6 in BM, 2 of whom relapsed (Figure C). Median follow-up was 82 months (mo) (range: 28-112.4). Fifty-six of 62 (90.3%) pts are alive; 28 are progression-free. Median PFS for the whole cohort was 89 mo. When PFS was analyzed according to whether MRD was detected or not (regardless of sensitivity), pts with U-MRD at the EOT had superior PFS vs pts with MRD+, whether the sample type used was BM (p=0.02, median NR vs 67 mo) or PBMC (p=0.02, median NR vs 74 mo), Figure A, B. When analyzed according to whether MRD was <10-6vs >/=10-6 (MRD6), 40/53 (75%) in BM and 13/21 (62%) in PBMC were MRD6+. For this analysis, pts were excluded if they had U-MRD but assay sensitivity did not reach at least 10-6. Despite smaller n, there were trends toward shorter PFS for pts with MRD6+ vs U-MRD6 (Figure C, D). Discussion The majority of pts with BM U-MRD4 after first-line FCR were MRD6+ and these patients had shorter PFS; MRD analysis with a more sensitive assay may therefore more accurately assign prognosis. Not accounting for sensitivity, a higher proportion of BM than PBMC samples were MRD+. Plasma analysis was uninformative as all pts MRD+ in plasma were MRD+ in simultaneous BM or PBMC samples. Defining prognostically-relevant thresholds for MRD using more sensitive methodology is important, particularly if U-MRD is used a surrogate for PFS in clinical trials or as an endpoint for treatment cessation. MRD6 may become increasingly relevant if venetoclax-based regimens and the addition of novel agents to chemoimmunotherapy achieve U-MRD6 in more patients than FCR. In this retrospective study, a number of samples did not achieve 10-6 sensitivity; optimization of sample collection is important to achieve 10-6 sensitivity in most pts. Finally, additional studies will be required to determine the risk for and kinetics of relapse in patients with low-level MRD6+. Disclosures Thompson: AbbVie: Honoraria, Research Funding; Gilead Sciences: Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Research Funding; Pharmacyclics: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Genentech: Honoraria, Membership on an entity's Board of Directors or advisory committees. Srivastava:Adaptive Biotechnologies: Employment. Hether:Adaptive Biotechnologies: Employment. O'Brien:Acerta: Research Funding; Sunesis: Consultancy, Research Funding; Regeneron: Research Funding; GlaxoSmithKline: Consultancy; Celgene: Consultancy; Amgen: Consultancy; Pharmacyclics: Consultancy, Research Funding; Vaniam Group LLC: Consultancy; Abbvie: Consultancy; Aptose Biosciences Inc.: Consultancy; Pfizer: Consultancy, Research Funding; TG Therapeutics: Consultancy, Research Funding; Janssen: Consultancy; Astellas: Consultancy; Alexion: Consultancy; Kite Pharma: Research Funding; Gilead: Consultancy, Research Funding. Jain:ADC Therapeutics: Research Funding; Celgene: Research Funding; Abbvie: Research Funding; Seattle Genetics: Research Funding; Pharmacyclics: Research Funding; Incyte: Research Funding; Genentech: Research Funding; Infinity: Research Funding; Astra Zeneca: Research Funding; BMS: Research Funding; Pfizer: Research Funding; Servier: Research Funding; ADC Therapeutics: Research Funding; Verastem: Research Funding; Seattle Genetics: Research Funding; Cellectis: Research Funding; Incyte: Research Funding; Celgene: Research Funding; Adaptive Biotechnologioes: Research Funding; Astra Zeneca: Research Funding; Pharmacyclics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Servier: Research Funding; Verastem: Research Funding; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Cellectis: Research Funding; Astra Zeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologioes: Research Funding; Verastem: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Astra Zeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees; ADC Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Verastem: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; ADC Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Servier: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novimmune: Honoraria, Membership on an entity's Board of Directors or advisory committees; Servier: Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novimmune: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees. Wierda:Genentech: Research Funding; AbbVie, Inc: Research Funding." @default.
- W2912706141 created "2019-02-21" @default.
- W2912706141 creator A5011548707 @default.
- W2912706141 creator A5021380291 @default.
- W2912706141 creator A5027575595 @default.
- W2912706141 creator A5028591457 @default.
- W2912706141 creator A5028845635 @default.
- W2912706141 creator A5033750986 @default.
- W2912706141 creator A5037981658 @default.
- W2912706141 creator A5038196228 @default.
- W2912706141 creator A5048180416 @default.
- W2912706141 creator A5058755419 @default.
- W2912706141 creator A5080883357 @default.
- W2912706141 creator A5084290698 @default.
- W2912706141 creator A5089428686 @default.
- W2912706141 date "2018-11-29" @default.
- W2912706141 modified "2023-10-18" @default.
- W2912706141 title "Undetectable-Minimal Residual Disease (U-MRD6) (10-6 sensitivity) Is Associated with Best Progression-Free Survival for Patients Who Achieve Bone Marrow Undetectable MRD4 (10-4 sensitivity) with First-Line FCR" @default.
- W2912706141 doi "https://doi.org/10.1182/blood-2018-99-117864" @default.
- W2912706141 hasPublicationYear "2018" @default.
- W2912706141 type Work @default.
- W2912706141 sameAs 2912706141 @default.
- W2912706141 citedByCount "1" @default.
- W2912706141 countsByYear W29127061412021 @default.
- W2912706141 crossrefType "journal-article" @default.
- W2912706141 hasAuthorship W2912706141A5011548707 @default.
- W2912706141 hasAuthorship W2912706141A5021380291 @default.
- W2912706141 hasAuthorship W2912706141A5027575595 @default.
- W2912706141 hasAuthorship W2912706141A5028591457 @default.
- W2912706141 hasAuthorship W2912706141A5028845635 @default.
- W2912706141 hasAuthorship W2912706141A5033750986 @default.
- W2912706141 hasAuthorship W2912706141A5037981658 @default.
- W2912706141 hasAuthorship W2912706141A5038196228 @default.
- W2912706141 hasAuthorship W2912706141A5048180416 @default.
- W2912706141 hasAuthorship W2912706141A5058755419 @default.
- W2912706141 hasAuthorship W2912706141A5080883357 @default.
- W2912706141 hasAuthorship W2912706141A5084290698 @default.
- W2912706141 hasAuthorship W2912706141A5089428686 @default.
- W2912706141 hasBestOaLocation W29127061411 @default.
- W2912706141 hasConcept C126322002 @default.
- W2912706141 hasConcept C127413603 @default.
- W2912706141 hasConcept C143998085 @default.
- W2912706141 hasConcept C21200559 @default.
- W2912706141 hasConcept C24326235 @default.
- W2912706141 hasConcept C2779823535 @default.
- W2912706141 hasConcept C2780007613 @default.
- W2912706141 hasConcept C71924100 @default.
- W2912706141 hasConceptScore W2912706141C126322002 @default.
- W2912706141 hasConceptScore W2912706141C127413603 @default.
- W2912706141 hasConceptScore W2912706141C143998085 @default.
- W2912706141 hasConceptScore W2912706141C21200559 @default.
- W2912706141 hasConceptScore W2912706141C24326235 @default.
- W2912706141 hasConceptScore W2912706141C2779823535 @default.
- W2912706141 hasConceptScore W2912706141C2780007613 @default.
- W2912706141 hasConceptScore W2912706141C71924100 @default.
- W2912706141 hasIssue "Supplement 1" @default.
- W2912706141 hasLocation W29127061411 @default.
- W2912706141 hasOpenAccess W2912706141 @default.
- W2912706141 hasPrimaryLocation W29127061411 @default.
- W2912706141 hasRelatedWork W1882523775 @default.
- W2912706141 hasRelatedWork W1980656001 @default.
- W2912706141 hasRelatedWork W2007222850 @default.
- W2912706141 hasRelatedWork W2232092255 @default.
- W2912706141 hasRelatedWork W2399001313 @default.
- W2912706141 hasRelatedWork W2428088476 @default.
- W2912706141 hasRelatedWork W2897496508 @default.
- W2912706141 hasRelatedWork W3030951506 @default.
- W2912706141 hasRelatedWork W3163033016 @default.
- W2912706141 hasRelatedWork W3209511237 @default.
- W2912706141 hasVolume "132" @default.
- W2912706141 isParatext "false" @default.
- W2912706141 isRetracted "false" @default.
- W2912706141 magId "2912706141" @default.
- W2912706141 workType "article" @default.